Watch the institutional video

WATCH THE VIDEO

Vaccine Production Center

The Vaccine Production Center [in Portuguese Centro de Produção de Vacinas or CPV]. Project was originally conceived based on the need to resume the manufacturing of Diphtheria, Tetanus and Hepatitis B vaccines suspended in 2012. The concept of the Project is to construct a vertical building consisting of seven (7) different and fully independent vaccine plants to the above mentioned vaccines  which also include an expansion area for vaccines production process. The aim is to meet the demand of vaccines from the local Ministry of Health´s within the Nacional Imunization Program.

Considering the manufacturing plants will be built in compliance with local and international regulations from the Brazilian Health Surveillance Agency (ANVISA) and the World Health Organization (WHO) with the objective to obtain WHO Prequalification current expectations under consideration comprise supplying selected vaccines to foreign markets.  

CPV manufacturing plants will be built with the concept of vertical production. The multiple-floor building will be designed and built with innovative technology, validated control systems and validated manufacturing systems. The most modern and currently available automation systems will be used in this building matching those found in leading global pharmaceutical companies.

The production area of each plant will have two support areas. The first, for preparing culture media and buffer solutions. The second, for washing, preparing and sterilizing auxiliary materials. Both areas will work simultaneously and in parallel with all other operational areas.

Vaccine Produced

HPV

In maintenance

Hepatitis A

In maintenance

Hepatitis B

Hepatitis B is transmitted via contact with bodily fluids and is still among the worst threats to public health leading to about 1 million deaths per year. In addition to the cases of death, hundreds of millions of people suffer from chronic infection many of whom develop cirrhosis and liver cancer ... Read more here

Acellular Pertussis

Whooping cough or pertussis is a contagious acute infectious disease which compromises and adheres to the cilia of the respiratory tract (trachea and bronchi) and is caused by Bordetella pertussis bacteria ... Read more here

Diphtheria

Diphtheria is an infectious contagious acute disease caused by Corynebacterium diphtheriae which causes inflammation of the mucous lining of the throat, nose, trachea and bronchi, inflammation occurs in the mucous membranes of the upper airways or in small skin wounds ... Read more here

Tetanus

Tetanus is a severe acute infectious disease caused by a neurotoxin produced by Clostridium tetani bacteria which enters the body through open wounds or skin lesions and causes muscle spasms ... Read more here

Platform

Future expansion area for production of another vaccine

Public Call

On 18th May 2020, Fundação Butantan made a Public Call that was devised by Instituto Butantan in which an innovative solution for the construction of a new building with seven different and fully independent vaccine manufacturing plants was solicited. The overarching lines of the EPC turnkey project were live-streamed on a video that is available on YouTube.

 

The complete Public Call Notice, all supporting technical documentation and video are available here.

In addition to those areas and directly linked to the vaccine manufacturing area every floor will also count on cold rooms, offices, a mezzanine for window-visiting, dressing rooms, elevators and additional support areas.

The most innovative characteristic of this Project is that it will be possible to manufacture different types of vaccines in one sole building. Each productive area of the building will operate in a fully independent manner since every utility, process equipment, operator and area is entirely dedicated to the manufacturing of one vaccine only. The industrial plant will thus comply with Good Manufacturing Practices (GMP), World Health Organization (WHO) and the Food and Drug Administration (FDA) regulations as well as with the applicable Biosafety legislation for the manufacturing of immunobiologicals.